1. High levels of lipoprotein are an independent causal risk factor for ASCVDs.
2. Mechanisms include increased atherogenesis, inflammation and thrombosis.
3. Lipoprotein(a) [Lp(a)] is predominantly a monogenic CV risk determinant, with =70% to ≥90% of interindividualized heterogeneity in levels being genetically determined.
4. The two major protein components of Lp(a) particles are apoB100 and apolipoprotein (a).
5. Lp(a) remains a risk factor for CVD development even in the setting of effective reduction of plasma LDL-C and apoB100.
6. Despite its demonstrated contribution to ASCVD burden, we presently lack standard and harmonization of assays, universal guidelines for diagnosing and providing risk assessment, and targeted treatments to lower Lp(a).
7. There is a clinical need to understand the genetic and biological basis for variation in Lp(a) levels and its relationship to disease in different ancestry groups.
8. Lipoprotein apheresis is approved for reduction of levels if Lp(a) is >60 mg/dL.
9. New targeted therapies will hopefully provide insights into the prevention of ASCVD.
Dr. Kris Vijay, MD, FACP, FACC, FNLA received his medical degree from the Kasturba Medical College. University of Mysore. India. in 1979 and postgraduate training in medicine in Bombay India in Oxford UK and in Rochester New York. He served a fellowship in endocrinology and diabetes at the University of Southampton UK and completed a fellowship in cardiology at Good Samantan Medical Center. University of Arizona in Phoenix He also holds a Master of Science degree in Clinical Research Design and Statistical Analysis from the University of Michigan He is a member of the clinical cardiology council as well as council for Atherosclerosis. Thrombosis and Vascular Biology and received the Govemor s award from Health Services Advisory Group (HSAG). October 2002 He was awarded the Jerome Markowitz award for career achievement by SASAT in 2013 and received an award from American College of Cardiology in 2013 for 3 years of prolific work in pursuit of quality education. mutually beneficial partnership and advocacy.
Subscribe To Our Newsletter
Filter out the noise and nurture your inbox with health and wellness advice that's inclusive and rooted in medical expertise.
Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks
Please update your details